BioCardia Inc
NASDAQ:BCDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Ozner Water International Holding Ltd
HKEX:2014
|
CN |
|
Encres Dubuit SA
PAR:ALDUB
|
FR |
|
G
|
Golden Matrix Group Inc
NASDAQ:GMGI
|
US |
BioCardia Inc
Total Current Liabilities
BioCardia Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BioCardia Inc
NASDAQ:BCDA
|
Total Current Liabilities
$3.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Total Current Liabilities
$641.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
37%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
BioCardia Inc
Glance View
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. The company is headquartered in Sunnyvale, California and currently employs 28 full-time employees. The company is focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Its lead therapeutic candidates are based on the CardiAMP Cell Therapy System, a platform which provides an autologous bone marrow-derived cell therapy for treatment in two clinical indications, such as ischemic heart failure and refractory angina resulting from chronic myocardial ischemia. Its second therapeutic platform is an investigational bone marrow derived allogeneic off-the shelf Neurokinin-1 Receptor Positive mesenchymal stem cell (MSC) therapy for the treatment of cardiac and pulmonary disease. The company has three enabling device product lines: the CardiAMP cell processing system, the Helix biotherapeutic delivery system (Helix), and the Morph vascular access product line (Morph). The company is advancing therapeutic candidates for heart failure, chronic myocardial infarction, and acute respiratory distress syndrome.
See Also
What is BioCardia Inc's Total Current Liabilities?
Total Current Liabilities
3.6m
USD
Based on the financial report for Jun 30, 2025, BioCardia Inc's Total Current Liabilities amounts to 3.6m USD.
What is BioCardia Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-4%
Over the last year, the Total Current Liabilities growth was -11%. The average annual Total Current Liabilities growth rates for BioCardia Inc have been 6% over the past three years , -4% over the past five years .
